GlaxoSmithKline, Cancer Research Technology and Manchester University have formed an alliance that taps into the potential of epigenetics to generate new cancer drugs.
Researchers believe that epigenetic alterations, i.e., molecular modifications affecting gene activity, hold as much importance as genetic mutations in a cell’s transformation to cancer, and that understanding the related mechanisms could eventually have a significant impact on cancer prevention, detection and therapy. Read the full story
In other GSK news, the company received a recommendation from Europe's regulator for approval of a two-dose schedule for Cervarix, which is currently licensed as a three-dose cervical cancer vaccine. Read the full story